Paradigm Biocapital Advisors LP Viridian Therapeutics, Inc.\De Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,895,689 shares of VRDN stock, worth $60.8 Million. This represents 2.37% of its overall portfolio holdings.
Number of Shares
2,895,689
Previous 2,896,349
0.02%
Holding current value
$60.8 Million
Previous $37.7 Million
74.83%
% of portfolio
2.37%
Previous 1.52%
Shares
12 transactions
Others Institutions Holding VRDN
# of Institutions
179Shares Held
76.8MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$100 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$92.8 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$81.5 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$78.8 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$72.4 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $838M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...